Mergers & Acquisitions - Licensing

Filter

Current filters:

Licensing

Popular Filters

55 to 79 of 1740 results

Are you overlooking the “X Factor” in Biopharma M&A? asks JLL expert

Are you overlooking the “X Factor” in Biopharma M&A? asks JLL expert

12-03-2014

When Merck & Co acquired Schering-Plough in 2009, the corporate real estate team reduced the combined…

ManagementMerck & CoMergers & AcquisitionsPharmaceutical

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech

11-03-2014

Caisson Biotech, a wholly-owned subsidiary of Heparinex and owner of a patented heparosan-based drug…

BiotechnologyCaisson BiotechDiabetesInflammatory diseasesLicensingMetabolicsNovo Nordisk

KYTHERA regains rights to ATX-101 outside USA and Canada from Bayer

KYTHERA regains rights to ATX-101 outside USA and Canada from Bayer

11-03-2014

US biotech firm KYTHERA Biopharmaceuticals says it has re-acquired all rights outside of the USA and…

ATX-101BayerDermatologicalsKYTHERA BiopharmaceuticalsLicensingNorth AmericaPharmaceutical

Valneva deal with Emergent BioSolutions for development of vaccines in the EB66 cell line

11-03-2014

European biotechnology company Valneva has signed a new research license agreement and transferred an…

BiotechnologyEB66 cell lineEmergent BioSolutionsLicensingVaccinesValneva

GSK increases stake in Indian Pharma subsidiary to 75%

GSK increases stake in Indian Pharma subsidiary to 75%

10-03-2014

UK pharma giant GlaxoSmithKline says that, following the voluntary open offer undertaken by its Indian…

Asia-PacificGlaxoSmithKlineIndiaMergers & AcquisitionsPharmaceutical

Debiopharm to acquire products or companies to expand activities at Swiss manufacturing facility

06-03-2014

Swiss independent drug developer Debiopharm say it plans to expand and optimize activities at Debiopharm…

DebiopharmMergers & AcquisitionsPharmaceuticalProduction

Eisai and Biogen Idec collaborate on Alzheimer’s disease treatments

Eisai and Biogen Idec collaborate on Alzheimer’s disease treatments

05-03-2014

US biotech firm Biogen Idec and Japanese drugmaker Eisai have entered into a collaboration to develop…

BAN2401BIIB037Biogen IdecBiotechnologyE2609EisaiLicensingNeurologicalResearch

Santen and TRACON link up for TRC105 in ophthalmology

04-03-2014

USA-based TRACON Pharmaceuticals and Japan’s Santen Pharmaceutical have entered into an exclusive agreement…

LicensingPharmaceuticalSanten PharmaceuticalsTRACON PharmaceuticalsTRC105

Oxford Gene Technology acquires Cytocell to expand genomics offering

Oxford Gene Technology acquires Cytocell to expand genomics offering

04-03-2014

Genetic research company Oxford Gene Technology has acquired Cambridge-based Cytocell, a leading provider…

BiotechnologyGeneticsMergers & AcquisitionsOxford Gene TechnologyUK

Abide Therapeutics in deal with Celgene on immune disorders research

03-03-2014

Privately-held Abide Therapeutics has entered into a strategic collaboration with US biotech firm Celgene…

AB101131Abide TherapeuticsBiotechnologyCelgeneImmunologicalsInflammatory diseasesLicensingMergers & Acquisitions

Ohr Pharma and Cold Spring Harbor Lab set up JV to develop trodusquemine

03-03-2014

US biotech firm Ohr Pharmaceutical and not-for-profit cancer research center Cold Spring Harbor Laboratory…

BiotechnologyDepYmedMergers & AcquisitionsOhr PharmaceuticalResearchtrodusquemine

Cumberland Pharma acquires Vaprisol from Astellas

03-03-2014

USA-based Cumberland Pharmaceuticals says it has acquired from the US subsidiary of Japan’s Astellas…

Astellas PharmaCumberland PharmaceuticalsHematologyLicensingNorth AmericaPharmaceuticalUSAVaprisol

Astellas amends license deal for isavuconazole with Basilea

01-03-2014

Japanese drug major Astellas Pharma has amended the license, co-development and co-promotion agreement…

Antibiotics and Infectious diseasesAstellas PharmaBasilea PharmaceuticaCanadaisavuconazoleLicensingNorth AmericaPharmaceuticalUSA

Perrigo transfers ELND005 assets; buys OTC products

01-03-2014

Drugmaker Perrigo has entered into a series of agreements with existing collaboration partner, Transition…

ELND005Mergers & AcquisitionsNeurologicalPerrigoPharmaceuticalResearchTransition Therapeutics

Roche collaborates with Discuva to combat life-threatening infections

28-02-2014

Swiss pharma major Roche and privately-held UK biotech firm Discuva have entered into a worldwide collaboration…

Antibiotics and Infectious diseasesDiscuvaLicensingPharmaceuticalResearchRoche

Israel's Clal Biotech in talks to sell Andromeda unit

28-02-2014

In an announcement to the Stock Exchange, Israeli firm Clal Biotechnology Industries said that, on February…

Andromeda BiotechBiotechnologyClal BiotechnologyDiabetesDiaPep277Mergers & AcquisitionsTeva Pharmaceutical Industries

Bayer to buy Chinese OTC/TCM drugmaker Dihon Pharma

27-02-2014

Germany’s leading pharma firm Bayer says it plans to acquire 100% of Dihon Pharmaceutical, a privately…

BayerDihon PharmaceuticalMergers & AcquisitionsPharmaceutical

Verastem acquires cancer stem cell inhibitor VS-4718 rights from Poniard

27-02-2014

US drug developer Verastem has acquired the license to VS-4718, which targets cancer stem cells, held…

BiotechnologyMergers & AcquisitionsOncologyPoniard PharmaceuticalsVerastemVS-4718

Merck returns rights to ridaforolimus to Ariad, whose 4th-qtr net loss widens

Merck returns rights to ridaforolimus to Ariad, whose 4th-qtr net loss widens

26-02-2014

US pharma giant Merck & Co has told partner Ariad Pharmaceutical that it is terminating its license agreement…

Ariad PharmaceuticalsFinancialLicensingMerck & CoOncologyPharmaceuticalridaforolimus

Way clear for Bayer to complete Algeta acquisition

26-02-2014

The way is now clear for Germany’s Bayer to acquire Norwegian pharmaceutical company Algeta, under…

AlgetaBayerMergers & AcquisitionsOncologyPharmaceuticalXofigo

Valneva initiates fourth antibody discovery program for Sanofi Pasteur

25-02-2014

European biotechnology company Valneva has initiated a fourth monoclonal antibody discovery program for…

Antibiotics and Infectious diseasesBiotechnologyLicensingResearchSanofiSanofi PasteurVaccinesValneva

Ardelyx licenses NaP2b to Sanofi in deal worth up to $198 million

Ardelyx licenses NaP2b to Sanofi in deal worth up to $198 million

25-02-2014

US venture-funded biopharmaceutical company Ardelyx has licensed its novel phosphate transport NaP2b…

ArdelyxAstraZenecaLicensingNaP2bNephrology and HepatologyPharmaceuticalSanofitenapanor

Celladon signs option agreement with Servier

24-02-2014

USA-based biotech firm Celladon has entered into an option agreement with French independent drugmaker…

BiotechnologyCelladonDiabetesLicensingServier

55 to 79 of 1740 results

Back to top